Veterinary Medicines

Vanguard plus 7 liofilizat in vehikel za raztopino za injiciranje za pse

Authorised
  • LEPTOSPIRA ICTEROHAEMORRHAGIAE INACTIVATED
  • Leptospira interrogans, Serogroup Canicola, serovar Canicola, Inactivated
  • Canine parvovirus, strain NL-35-D, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain N-CDV, Live
Download as PDF

Product identification

Medicine name:
Vanguard plus 7 liofilizat in vehikel za raztopino za injiciranje za pse
Active substance:
  • LEPTOSPIRA ICTEROHAEMORRHAGIAE INACTIVATED
  • Leptospira interrogans, Serogroup Canicola, serovar Canicola, Inactivated
  • Canine parvovirus, strain NL-35-D, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain N-CDV, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • LEPTOSPIRA ICTEROHAEMORRHAGIAE INACTIVATED
    40.00
    Protective Dose
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, Serogroup Canicola, serovar Canicola, Inactivated
    40.00
    Protective Dose
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain NL-35-D, Live
    10000000.00
    cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine parainfluenza virus, strain NL-CPI-5, Live
    1000000.00
    cell culture infective dose 50
    /
    1.00
    Dose
  • Canine adenovirus 2, strain Manhattan, Live
    1584.00
    cell culture infective dose 50
    /
    1.00
    Dose
  • Canine distemper virus, strain N-CDV, Live
    1000.00
    cell culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for solution for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Slovenia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Agency For Medicinal Products And Medical Devices Of The Republic Of Slovenia
Authorisation number:
  • NP/V/0347/001
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Slovenian (PDF)
Published on: 10/11/2021
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Slovenian (PDF)
Published on: 10/11/2021
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Slovenian (PDF)
Published on: 10/11/2021
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."